C4 Therapeutics (CCCC) Assets (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Assets of $328.9 million for Q1 2026, up 2.92% year-over-year from $319.5 million in Q1 2025, and down 8.41% quarter-over-quarter from $359.1 million in Q4 2025.
C4 Therapeutics (CCCC) Assets (2019 - 2026) Analysis & Trends
C4 Therapeutics' Assets history runs 8 years deep, the most recent figure standing at $328.9 million for Q1 2026.
- In Q1 2026, Assets rose 2.92% year-over-year to $328.9 million; the TTM figure through Mar 2026 stood at $328.9 million (up 2.92% YoY), while the FY2025 annual figure was $359.1 million, up 2.71% from the prior year.
- Assets for Q1 2026 stood at $328.9 million, down from $359.1 million in the prior quarter.
- The five-year high for Assets was $515.5 million in Q1 2022, with the low at $265.5 million in Q3 2025.
- The 5-year median for Assets is $376.1 million (2024), against an average of $379.7 million.
- The sharpest annual moves came in 2022 and 2025: Assets surged 37.83% in 2022, then slipped 29.4% in 2025.
- C4 Therapeutics' Assets stood at $430.8 million in 2022, then fell by 12.62% to $376.5 million in 2023, then slipped by 7.13% to $349.6 million in 2024, then grew by 2.71% to $359.1 million in 2025, then decreased by 8.41% to $328.9 million in 2026.
- Business Quant data shows CCCC's Assets at $328.9 million in Q1 2026, $359.1 million in Q4 2025, and $265.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 359.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 359.40 Mn |
| Mar 31, 2026 | 328.86 Mn |
| Dec 31, 2025 | 359.08 Mn |
| Sep 30, 2025 | 265.49 Mn |
| Jun 30, 2025 | 296.53 Mn |
| Mar 31, 2025 | 319.52 Mn |
| Dec 31, 2024 | 349.60 Mn |
| Sep 30, 2024 | 376.06 Mn |
| Jun 30, 2024 | 381.09 Mn |
| Mar 31, 2024 | 398.37 Mn |
| Dec 31, 2023 | 376.45 Mn |
| Sep 30, 2023 | 333.01 Mn |
| Jun 30, 2023 | 375.01 Mn |
| Mar 31, 2023 | 396.04 Mn |
| Dec 31, 2022 | 430.84 Mn |
| Sep 30, 2022 | 461.44 Mn |
| Jun 30, 2022 | 492.48 Mn |
| Mar 31, 2022 | 515.49 Mn |
| Dec 31, 2021 | 506.77 Mn |
| Sep 30, 2021 | 507.91 Mn |